AstraZeneca Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Dec 30, 2022 Top 10 Precision Oncology Stories in 2022: Liquid Biopsy, Radioligands, HER2-Low, Data Sharing Dec 20, 2022 NICE Backs Enhertu via Managed Access Program for Certain HER2-Positive Breast Cancer Patients Dec 19, 2022 AstraZeneca's Imfinzi Fails to Meet Primary Endpoint in PD-L1-high NSCLC Dec 9, 2022 Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug Dec 8, 2022 New HER2-Low Category Spurring Efforts to Understand Breast Cancer Biology, Develop Better Tests Premium Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Nov 29, 2022 AstraZeneca to Acquire Cell Therapy Firm Neogene Therapeutics Nov 14, 2022 EMA's CHMP Recommends Enhertu for HER2-Positive Gastric Cancer Nov 11, 2022 In Brief This Week: Oncotelic Therapeutics, VolitionRx, Genetron Health Nov 10, 2022 AstraZeneca Q3 Revenues From Oncology Products Grow 20 Percent Premium Oct 27, 2022 Keytruda Revenue Climbs 20 Percent in Q3 as Merck Continues Push Into Earlier-Stage Cancer Settings Premium Oct 27, 2022 Invitae, AstraZeneca Partner for Cholangiocarcinoma Study Using Ciitizen Data Platform Oct 18, 2022 Ikena Oncology to Study IK-930, Tagrisso Combo in EGFR-Mutant NSCLC Oct 4, 2022 FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Oct 3, 2022 Theseus Pharmaceuticals to Develop Pan-EGFR Inhibitor for Resistant NSCLC Patients Sep 29, 2022 Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2 Premium Sep 23, 2022 In Brief This Week: Seagen, Ideaya Biosciences, Cellistic, AstraZeneca, Kinnate Biopharma Sep 20, 2022 Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis Premium Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
